Atrial Fibrillation: Market Research Report

August 2010 | 301 pages | ID: A61EB4316C1EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the Global market for Atrial Fibrillation in US$ Million by the following segments: Advanced Mapping, Ablation Catheters, Surgical Ablation Devices, Introducers & Accessories, and Diagnostics.

Annual estimates and forecasts are provided for the period 2006 through 2015.

Also, the report provides market revenues for Atrial Fibrillation therapies for the years 2006 through 2015.

The report profiles 34 companies including many key and niche players such as AtriCure, Inc., Baxter International, Inc., Becton, Dickinson & Company, Biosense Webster, Inc., Boston Scientific Corp., Cardiome Pharma Corp., C.R. Bard, Inc., Cardima, Inc., Endosense SA, Medtronic, Inc., Sanofi-Aventis, Sorin SpA, Spectrasonics, Inc., St. Jude Medical, Inc., and Zimmer Holdings, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definition and Scope of Study

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

Atrial fibrillation: A Prelude
Market Outlook
The Market Opportunity

Table 1. Population Growth (60+ age group) over the Period 2009-2013 (includes corresponding Graph/Chart)

Side-Effects and Ineffectiveness Mar Current AF Drug Therapy Option
Non-Pharmacotherapy to Exhibit Strong Growth

Table 2. Global Atrial Fibrillation Market (2007): Annual Atrial Fibrillation Procedures by Region/ Country - US, Europe and Rest of World (includes corresponding Graph/Chart)

Ablation Catheters to Bolster Market Growth for AF Devices
Increased Popularity of Ablation Catheters Drive Product Developments
Clinical Trials and Technology Enhancements Propel AF Ablation Market
Convenience and Safety Brings Novel Anticoagulants to the Forefront
Diagnostic EP Catheters Poised for Robust Growth
Mapping Features in Diagnostic EP Catheters Contribute to Growth
Balloon Catheters: Most Effective Treatment for Paroxysmal AF
New Technologies in Ablation

2.TREATMENT OF ATRIAL FIBRILLATION

Treatment Objectives for Atrial Fibrillation
Existing Treatment Protocols: Pharmacological and Interventional Approach
Pharmacological Treatment
Rate and Rhythm Control
Rate Control
Popular Drugs Used for Rate Control
Rhythm Control
Popular Drugs Used for Rhythm Control
List of Different Types of Antiarrhythmic Drugs
Stroke Prevention through Drugs
Anticoagulation
Cardioversion
Chemical Cardioversion
Electrical Cardioversion

Table 3. Global Atrial Fibrillation Market (2007): Percentage Response Rate of Most Effective Therapy for Treatment of Atrial Fibrillation by Drugs - Diltiazem (Cardizem), Electrical Cardioversion, Amiodarone (Cordarone), Propranolol, Ibutilide (Corvert) and Other (includes corresponding Graph/Chart)

Select Anti-Arrhythmic drugs
Multaq® (dronedarone)
Amiodarone
Digoxin (Lanoxin)
Non-Pharmacological Treatment
Ablate and Pace Technique
Left Atrial Appendage Closure – Alternative to Anticoagulation
Catheter Ablation
Techniques of Catheter Ablation
Patient Selection
Results of AF Ablation
Complications
Post-Ablation Considerations
Pulmonary Vein Isolation
Cox Maze
Minimally-Invasive Maze Techniques
Standard Surgical Ablation
HIFU Surgical Ablation
Other Recent Approaches to Ablation

3.ELECTROPHYSIOLOGY ABLATION – A REGIONAL PERSPECTIVE

Europe
Physician’s Confidence and New Product Launches Fuel Growth
Inorganic Growth to Keep Alive European Electrophysiology Market
Technological Sophistication to Drive Growth in European EP Ablation Catheters Market
Cost Cutting Measures Pull Back European EP Ablation Catheters Market
Technological Breakthroughs Augur Growth in European Cardiac Rhythm Management
United States
Key Statistical Findings

Table 4. US Atrial Fibrillation Prevalence for the Period 2010-2050 (includes corresponding Graph/Chart)

Table 5. US Atrial Fibrillation Market Occurrence by Age and Gender: 2006 (includes corresponding Graph/Chart)

Table 6. US Atrial Fibrillation Market (2006): Percentage Utilization of Medical Service by Patients with AF (includes corresponding Graph/Chart)

Table 7. US Atrial Fibrillation Market (2006): Average Annual Direct-Per-Patient Costs Incurred by Patients with AF (includes corresponding Graph/Chart)

Table 8. US Atrial Fibrillation Therapeutic Market (2007): Percentage Breakdown of Revenues by Category - Amiodarone, Sotalol, Propafenone, Fiecainide, and Others (includes corresponding Graph/Chart)

Table 9. US Healthcare Spending (in US$ trillion): 2008 and 2017

Table 10. US ICD Market Share (2010): Percentage Breakdown of Market Share by Players - Medtronic, Boston Scientific, St. Jude Medical and Others (includes corresponding Graph/Chart)

US Electrophysiology Ablation Catheters Market: An Overview
Atrial Fibrillation Procedures on Growth Trajectory
Manual Steering Procedures Score over Robotic and Remote Magnetic Guidance Systems
China
Canada

4.ATRIAL FIBRILLATION - THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS

Introduction
What is Atrial Fibrillation?
History of AF
Risk Factors
Controllable Risk Factors
Non-Controllable Risk Factors
Steps to Reduce Risk Factors and Treat Underlying Reasons
Preventive Measures
Causes of Atrial Fibrillation
Symptoms of Atrial Fibrillation
Consequences of Atrial Fibrillation
Morbidity and Mortality Consequences
AF Significantly Impacts Quality of Life
Impact on Healthcare System
Patterns of Atrial Fibrillation
First Detected AF
Paroxysmal Atrial Fibrillation
Persistent Atrial Fibrillation
Chronic or Permanent Atrial Fibrillation
Postoperative Atrial Fibrillation
Classification of Atrial Fibrillation
Lone Atrial Fibrillation (LAF)
Non-valvular AF
Secondary AF
Identification of Atrial Fibrillation
Diagnosis or Evaluation of AF
Minimal Evaluation Methods
Routine Blood Diagnosis
Electrocardiogram
Tilt-Table Test
Physical Examination and History
Extended Evaluation Methods
Event Recording
Echocardiography
Trans-esophageal Echocardiogram
Chest X-Ray
Electrophysiology Study
Exercise-Stress Testing
Ambulatory Holter Monitoring
Cardiac Mapping
Effects of Atrial Fibrillation
Progressive Atria Fibrosis
Thromboembolism
Research on Atrial Fibrillation

5.CLINICAL TRIALS

St. Jude Announces IRASE AF Clinical Trial to Evaluate Cardiac Ablation Catheter System for Treating AF
Biosense Webster Supports Landmark Global CABANA Clinical Trial for Atrial Fibrillation
Cardiome Pharma Announces Completion of European Comparator Study
Mayo Clinic Receives Grant to Study Treatment for Atrial Fibrillation
Medtronic Completes STOP-AF Trial of Medtronic Arctic Front® CryoAblation Catheter System
The Mount Sinai Medical Center Uses Atrial Ablation Catheter of CardioFocus
US Cardiologists Carry Out First 3D Imaging of Complex Cardiac Anatomy
Warfarin Therapy Found Effective for Atrial Fibrillation
ABLATE Clinical Trial of AtriCure for Evaluation of Isolator SynergyTM Bipolar Ablation System
Ablation Frontiers’ Atrial Fibrillation Cardiac Ablation Technology Evaluated
Montreal Heart Institute Organizes Global Clinical Trial
deCODE Genetics Highlights Clinical Utility of deCODE AFTM
Boehringer Ingelheim Announces Enrollment for RE-LY Trial
RF Ablation Generator and Catheter Proves to be Successful in Atrial Fibrillation
ATI-2042 Proves Successful in Atrial Fibrillation
NaviStar® ThermoCool Catheter Proves Better Treatment Alternative than AAD Therapy

6.PRODUCT APPROVALS

St. Jude Medical's Anthem RF CRT-P and Accent RF Pacemaker Receive FDA Approval
Sorin Group Acquires Regulatory Approval to Market Pacemakers in Japan
NaviStar Catheter Receives FDA Approval for Atrial Fibrillation
Multaq Receives EU Approval for Atrial Fibrillation
Multaq Receives Approval from Health Canada for Atrial Fibrillation
Sanofi-aventis Receives FDA Approval for Multaq 400 mg Tablets
St. Jude Medical's Current Accel and AnalyST Accel ICDs Receive CE Mark
Biosense Webster Manufactured Devices Receive FDA Approval
Cardima Obtains CE Mark Approval for Surgical Ablation Probe with Stabilization Sheath
St. Jude Receives CE Mark Approval for SJM ConfirmTM ICM
CV Therapeutics Manufactured Ranexa Obtains FDA Approval

7.RECENT INDUSTRY ACTIVITY

dosense and Biotronik Sign Global Distribution Agreement
Merck Acquires Commercial Rights for Betrixaban
Erasmus University Medical Centre and CLT Israel Sign Joint Venture Agreement
Gilead Sciences to Take Over CV Therapeutics
BMS, Teijin Pharma and Nissan Chemical Industries form Worldwide Collaboration
Medtronic Acquires Ablation Frontiers
Merck Signs Collaboration Agreement with Cardiome
Royal Philips Collaborates with Bard to Co-Develop Clinical Tools for Arrhythmias
Medtronic Acquires CryoCath Technologies
Heritage Pharma and Ipca Laboratories Enter into Strategic Alliance
Nissan Chemical to Seek Overseas Licensee for Atrial Fibrillation Drug
Boston Scientific Acquires CryoCor
St. Jude Signs Merger Agreement with MediGuide
St. Jude Medical Acquires EP MedSystems
Cardima Signs Marketing Contract with On-X Life Technologies
Angiotech Pharmaceuticals Signs Licensing Agreement with Symphony Medical
AtriCure Acquires Frigitronics CCS-200 Product Range from Cooper Surgical

8.PRODUCT LAUNCHES

Sorin Introduces Implant of Advanced Cardiac Resynchronization Therapy Defibrillator
Sanofi-aventis Launches Multaq in the US
Medtronic Launches Insertable Cardiac Monitor in US
St. Jude Medical Launches Medical Devices for Heart Rhythm Disorders
eCardio Diagnostics Launches AFISTM Informatics Solution
BIOTRONIK Unveils Lumax 540 Devices for Cardiac Rhythm Management in the US
CardioNet Launches Improved CardioNet AF Management Program
LifeWatch Launches First Commercial LifeWatch Atrial Fibrillation Patient Care Program
CryoCath Technologies Launches Arctic Front in Belgium, Spain and Italy
ATS Medical Introduces ATS CryoMaze Clamp for Surgical Ablation

9.FOCUS ON SELECT MAJOR PLAYERS

AtriCure, Inc. (US)
Baxter International, Inc. (US)
Becton, Dickinson & Company (US)
Biosense Webster, Inc. (US)
Boston Scientific Corp. (US)
Cardiome Pharma Corp. (Canada)
C.R. Bard, Inc. (US)
Cardima, Inc. (US)
Endosense SA (Switzerland)
Medtronic, Inc. (US)
Sanofi-Aventis (France)
Sorin SpA (Italy)
Spectrasonics, Inc. (US)
St. Jude Medical, Inc. (US)
Zimmer Holdings, Inc. (US)

10.GLOBAL MARKET PERSPECTIVE

Table 11. World Recent Past, Current & Future Analysis for Atrial Fibrillation by Segment - Advanced Mapping, Ablation Catheters, Surgical Ablation Devices, Introducers & Accessories, and Diagnostics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 12. World 10-Year Perspective for Atrial Fibrillation by Segment - Percentage Breakdown of Dollar Sales by Advanced Mapping, Ablation Catheters, Surgical Ablation Devices, Introducers & Accessories and Diagnostics for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

Table 13. Atrial Fibrillation Therapies Worldwide: Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 34 (including Divisions/Subsidiaries - 41)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)